why it is moving

Twist Bioscience Corp (NASDAQ:TWST) shares are trading higher after the company released first-quarter 2024 earnings and increased its FY24 revenue guidance. The DNA synthesis company reported first-quarter sales of $71.5 million, up 32% Y/Y from $54.2 million a year ago, beating the...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. Revenues increased 1% to $3.43 billion, beating the consensus of $3.29 billion. Total revenues excluding Ronapreve (COVID-19 treatment) reached $3.44...

Friday, Cigna Corporation (NYSE:CI) reported fourth-quarter 2023 sales of $ 51.15 billion, up 12% Y/Y, beating the consensus of $48.89 billion, reflecting strong growth across Evernorth Health Services and Cigna Healthcare. Cigna Healthcare’s fourth quarter adjusted sales...

Apple, Inc.’s (NASDAQ:AAPL) fiscal year 2024 first-quarter earnings report presented a mixed picture, prompting apprehensive traders to push the stock lower in premarket trading on Friday. The company reported first-quarter earnings per share of $2.18 and revenue of $119.6 billion....

Wednesday, Novartis AG (NYSE:NVS) reported fourth-quarter 2023 net sales of $11.42 billion, up 8% (up 10% at constant currency, cc) driven by volume growth of 13 percentage points. The sales fell short of the consensus of $11.76 billion. Generic competition had a negative impact...

Tuesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 3 program (two Phase 3 trials) for the selective NaV1.8 inhibitor, VX-548, for moderate-to-severe acute pain.  Treatment with VX-548 following abdominoplasty or bunionectomy surgery...

Arcus Biosciences Inc (NASDAQ:RCUS) shares are trading higher after Gilead Sciences Inc (NASDAQ:GILD) amended their collaboration agreement and announced a separate equity investment of $320 million in Arcus stock at $21.00 per share.  The equity investment and...

HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and its two Gilead Science Inc (NASDAQ:GILD)-...

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.  The Phase 1 dose escalation study is being...

Vera Therapeutics Inc (NASDAQ:VERA) announced 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).  Data from the OLE show the consistent and sustained reductions of serum galactose-...

Alaska Air Group Inc (NYSE:ALK) reported fourth-quarter operating revenue of $2.55 billion, up 3% Y/Y, in-line with the consensus of $2.55 billion. The company reported adjusted EPS of $0.30, down from $0.92 a year ago, beating the consensus estimate of $0.18. Alaska said that it is...

LAVA Therapeutics NV (NASDAQ:LVTX) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with LAVA-1207 in patients with therapy refractory metastatic ...

American Airlines Group Inc (NASDAQ:AAL) reported a 75% drop in adjusted earnings to $0.29 per share in the fourth quarter of 2023 but still came in well above the consensus estimate of $0.10. Total revenue decreased 1% to $13.06 billion, just beating estimates of $13.02 billion. For...

Humana Inc (NYSE:HUM) shares nosedived after the company released dismal fourth quarter 2023 earnings. The company reported a Q4 adjusted EPS loss of $(0.11), a turnaround from EPS income of $1.97 a year ago, missing the consensus of $(0.05). The fourth quarter results reflect an...

Evaxion Biotech A/S (NASDAQ:EVAX) announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens named Endogenous Retroviruses (ERVs). ERVs are remnants of ancient viruses lying dormant in a human genome. ERVs are...